BioMarin Announces Second Quarter 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $119 at Deutsche Bank
August 3, 2017 8:52 AM EDTDeutsche Bank raised its price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $119.00 (from $118.00) while maintaining a Buy rating.
Analyst Andrew Peters commented, "Todays results and hemophilia update continue to support our bullish view on BioMarins diversified and high-growth portfolio. Second quarter... More
BioMarin Pharma (BMRN) Reports In-Line Q2 EPS
August 2, 2017 4:27 PM EDTBioMarin Pharma (NASDAQ: BMRN) reported Q2 GAAP EPS of ($0.21), in-line with the analyst estimate of ($0.21). Revenue for the quarter came in at $317.4 million versus the consensus estimate of $308.96 million.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
... More